Detrusor Underactivity as an HCN-mediated Failure of Resilience in Aging

逼尿肌活动不足是 HCN 介导的衰老过程中弹性丧失的原因

基本信息

项目摘要

ABSTRACT Detrusor Underactivity (DU) is a voiding impairment due to insufficient bladder muscle effort to ensure timely and efficient bladder emptying. As a disorder of volume management, DU is often associated with incontinence and other urinary symptoms, especially in later life. Despite the term suggesting a bladder muscle disorder, a key characteristic of DU is loss of sensitivity to bladder volume. Like DU, aging is also associated with loss of volume sensitivity. Moreover, aging is characterized by increasing risk of failure to adapt to biologic challenge, i.e. loss of resilience. We therefore propose that DU is not a detrusor disease, rather it is a manifestation of the nonresilient end of the spectrum of bladder sensory changes of aging. In this project we will investigate the role of a “pacemaker” ion channel in the age evolution of a control mechanism critical to bladder volume sensitivity. We hypothesize that DU is associated with the more severe age- associated changes. This knowledge will allow us to determine the control factors contributing to the loss of successful, resilient aging and the resulting non-resilience manifested as DU. To accomplish these goals will use our established mouse cystometry model to test urinary resilience and define a DU group separate from age groups. Our research methods will include single cell genomic sequencing, electrophysiology, molecular/cellular investigations, and correlative tissue-level experiments in order to address our objective. By taking advantage of the uniquely available combined expertise within the UConn Center on Aging, Neurosciences department, and on-site Jackson laboratory, we will address the goal of identifying DU pathophysiology and contributing to an improved therapeutic model which recognizes DU as an adaptive failure.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Phillip Paul Smith其他文献

Phillip Paul Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Phillip Paul Smith', 18)}}的其他基金

Urinary Symptoms and Incontinence in Aging Reflect Loss of Lower Urinary Tract Resilience
衰老过程中的尿路症状和尿失禁反映了下尿路弹性的丧失
  • 批准号:
    10406949
  • 财政年份:
    2021
  • 资助金额:
    $ 58.86万
  • 项目类别:
Urinary Symptoms and Incontinence in Aging Reflect Loss of Lower Urinary Tract Resilience
衰老过程中的尿路症状和尿失禁反映了下尿路弹性的丧失
  • 批准号:
    10213891
  • 财政年份:
    2021
  • 资助金额:
    $ 58.86万
  • 项目类别:
Regulatory Mechanisms in a Homeostatic Model of Geriatric Voiding Problems and Incontinence
老年排尿问题和失禁稳态模型的调节机制
  • 批准号:
    9519807
  • 财政年份:
    2016
  • 资助金额:
    $ 58.86万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 58.86万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 58.86万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 58.86万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 58.86万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 58.86万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 58.86万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 58.86万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 58.86万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 58.86万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 58.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了